Sunshine Biopharma Inc reports results for the quarter ended in June - Earnings Summary

Sunshine Biopharma

19/08/2024 14:31

* Sunshine Biopharma Inc  SBFM.OQ  reported a quarterly
adjusted
loss of $9.94​​ per share for the quarter ended in June.  The
lone analyst forecast for the quarter was for a loss of $7.40
per share. 
    * Revenue was $9.30 million​; analysts expected $9.00
million. 
    * Sunshine Biopharma Inc's reported EPS for the quarter was
a loss
of $9.94​.
    * The company reported a quarterly loss of $494.3 thousand.
    * Sunshine Biopharma Inc shares had fallen by 65.0% this
quarter and lost 99.5% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Sunshine
Biopharma Inc is $300.00 
This summary was machine generated from LSEG data August 19 at
01:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -7.40          -9.94          Missed
 Mar. 31 2024      -20.80         -40.00         Missed
 Dec. 31 2023      -60.00         -1.00 hundred  Missed
 Sep. 30 2023      -1.20 hundred  -80.00         Beat